Posted by Michael Wonder on 09 Mar 2022
NICE unable to provide guidance on a new use of lenalidomide
9 March 2022 - NICE is unable to make a recommendation on the use of lenalidomide for the treatment of patients with relapsed or refractory mantle cell lymphoma.
This is because Celgene did not provide an evidence submission.
